Expanding US momentum and commercial progress for Remplir™
Orthocell CEO and MD, Paul Anderson, presented at two investor-facing events on 31 March 2026, providing an in-depth update on the Company’s commercial progress and global expansion strategy.
Ausbiz Capital Investor Connect
Presenting to a broad investor audience at the Ausbiz Capital Investor Connect Biotech & Pharmaceuticals Special, the presentation focused on the scale of the US opportunity for Orthocell and the early execution of the Company’s commercial strategy. Paul emphasised the sheer size of the US peripheral nerve market, with more than 700,000 procedures performed annually in the United States, the majority of which still rely on traditional suturing techniques. He also noted that the Company could achieve cash breakeven with only 5,000- 6,000 procedures per year – representing less that 1% of the addressable market. He also highlighted the growth in surgeon adoption of Remplir™, describing the product as addressing a clear unmet need in surgical practice:“Surgeons are liking what they’re feeling. They’re liking the way that it works in theatre for them. [As a result] we’re seeing both directed growth and organic growth, which is a great sign of a fantastic product. From a unit sales perspective, we’ve also seen a significant increase — from one patient in June to between 110–120 patients in the last quarter.”
Broker Meets Biotech, Perth
In the afternoon, Paul presented to brokers and investors in Perth, providing a more detailed view of Orthocell’s commercial performance and growth trajectory. The session expanded on the early traction outlined in the Ausbiz presentation, with data demonstrating rapid uptake since launch. Key highlights include:
Surgeon numbers increased from 1 to 48 in 9 months
Hospitals expanded to 52 sites since first sale
Quarterly unit sales grew to over 110-120 units
Paul then compared that growth over a few quarters with the Australia & New Zealand market growth and how we plan to replicate that in the US market.
Paul also provided further clarity on the Company’s pathway to profitability, reiterating that breakeven can be achieved at approximately 5,000–6,000 procedures annually, supported by a relatively modest base of active surgeons. This target is considered achievable based on current pipeline activity and prior experience in Australia, where the Company has already demonstrated strong adoption across hundreds of surgeons and hospitals.The presentation also highlighted emerging opportunities to expand the use of Remplir™ into prostate cancer surgery, where the product is being used to support nerve preservation and improve post-operative functional outcomes. This expansion has the potential to meaningfully increase the total addressable market for Remplir™, reinforcing the broader growth profile of the platform.Download the Investor Presentation
In the afternoon, Paul presented to brokers and investors in Perth, providing a more detailed view of Orthocell’s commercial performance and growth trajectory. The session expanded on the early traction outlined in the Ausbiz presentation, with data demonstrating rapid uptake since launch.
Key highlights include:
Paul also provided further clarity on the Company’s pathway to profitability, reiterating that breakeven can be achieved at approximately 5,000–6,000 procedures annually, supported by a relatively modest base of active surgeons. This target is considered achievable based on current pipeline activity and prior experience in Australia, where the Company has already demonstrated strong adoption across hundreds of surgeons and hospitals.
The presentation also highlighted emerging opportunities to expand the use of Remplir™ into prostate cancer surgery, where the product is being used to support nerve preservation and improve post-operative functional outcomes. This expansion has the potential to meaningfully increase the total addressable market for Remplir™, reinforcing the broader growth profile of the platform.
Download the Investor Presentation